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Abstract: Limited evidence exists that humans mount a mutation-
speciﬁc T cell response to epithelial cancers. We used a
whole-exomic-sequencing-based approach to demonstrate that
tumour-inﬁltrating lymphocytes (TILs) from a patient with meta-
static cholangiocarcinoma contained CD4+ T helper 1 (TH1) cells,
recognizing a mutation in the erbb2 interacting protein (ERBB2IP)
expressed by the cancer. After adoptive transfer of TILs, containing
about 25% mutation-speciﬁc polyfunctional TH1 cells, the patient
achieved a decrease in target lesions with prolonged stabilization
of the disease. Upon disease progression, the patient was retreated
with a >95% pure population of mutation-reactive TH1 cells and
again experienced tumour regression. These results provide evidence
that a CD4+ T cell response against a mutated antigen can be
harnessed to mediate regression of a metastatic epithelial cancer.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V.
T cell based cancer immunotherapy, the concept of utilizing
T cells to cure cancer patients, was until recently regarded with
scepticism. One of the main conceptual problems is that, physio-
logically, T cells recognize and eliminate cells that express non-
self proteins. These are not usually present in cancer cells that
instead express so called ‘‘tumour-associated antigens’’, which
are self-antigens expressed at different levels in cancer vs. normal
cells [1,2]. There are immunological consequences of this feature:
tumour-associated antigens are poor inducers of tumour-speciﬁc
T cells that do not expand in patients or poorly recognize the
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tumour-associated antigen-speciﬁc T cells are efﬁciently pro-
duced (for example by engineering T cells with a chimeric T cell
receptor (TCR) speciﬁc for tumour-associated antigens), the
T cells will not only target the tumour but also normal cells with
a clinical outcome that might be extremely severe [3]. However,
the concept that cancerous cells do not express immunogenic
non-self antigens changed after the demonstration that the
genetic alterations present in cancers can lead to the production
of new immunogenic ‘‘non-self’’ antigens that can be exploited to
induce effective tumour-speciﬁc T cell responses. T cell speciﬁc
tumour-associated neo-antigens were detected in melanoma
and were suggested to be the cause of the high immunogenicity
of this cancer.
In this new paper, Tran et al., make the very important dem-
onstration that such ‘‘neo antigens’’ are present and immuno-
genic not only in melanoma but also in a cancer of epithelial
origin, which account for 80% of all human cancers. Furthermore,
they not only demonstrated that T cells recognizing a mutated
version of a tumour-associated antigen can be detected in a
patient with metastatic cholangiocarcinoma but also that these
mutation-speciﬁc T cells unique to the patient’s cancer can be
harnessed to mediate regression of a metastatic epithelial cancer
(Fig. 1).
To demonstrate the presence of mutation-speciﬁc T cells, the
authors ﬁrst used a leading edge whole-exome sequencing based
approach to identify mutated candidate epitopes expressed in
lung metastases of a patient with bile duct cancer not responsive
to standard chemotherapy. The 26 detected mutated sequences
were expressed on autologous antigen presenting cells using con-
structed libraries of minigenes encoding the mutated sequences.
They then tested whether the patient’s tumour-inﬁltrating lym-
phocytes (TILs) recognized any of these mutations and demon-
strated that T cells inﬁltrating the patient’s tumour comprised
of T cells that recognized only a mutated version of the ERBB2-
interacting protein (ERBB2IP) but were unresponsive to the wild
type non-mutated ERBB2IP. These mutation-speciﬁc T cells were
CD4 cells, HLA-DQB1⁄0601 restricted, recognized a minimal epi-
tope composed of 13 amino acids and seemed to be of mono-oli-
goclonal origin since they were characterized for a very restricted
TCR usage. Direct evidences that these mutation-speciﬁc T cells
can be exploited for therapeutic purpose were obtained by show-
ing that adoptive cell transfer of a large quantity (42.4 billion) of
the expanded TILs, of which about 25% were CD4+ ERBB2IP muta-
tion-reactive T lymphocytes caused tumour regression and dis-
ease stabilization for approximately one year. This clinical14 vol. 61 j 1175–1177
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Fig. 1. A schematic of identiﬁcation of TILs that recognize a patient-speciﬁc mutation in a patient with epithelial cancer, followed by treatment of the patient using
adoptive cell therapy with TILs containing Vb22+ ERBB2IP mutation-reactive T cells.
International Hepatologyefﬁcacy was conﬁrmed after a second round of adoptive T cell
therapy in which 95% of the transferred cells were Vb22+
ERBB2IP mutation-reactive TH1 cells that caused an accelerated
tumour regression.
Therefore, by demonstrating that mutations present in epithe-
lial tumours produced new antigens able to induce T cells that
recognize the patient-speciﬁc mutated protein, Tran et al. bring
to the forefront an alternative strategy to generate T cells for
adoptive cell therapy and treat patients with common epithelial
cancers, where there is a low frequency of tumour-reactive
T cells. The results presented in this study are also encouraging
as CD4+ TH1 cells, other than CD8 CTL, can confer clinical beneﬁt
in targeting cancer.
Targeting sporadic or driver mutations unique to a patient’s
individual cancer with mutation-reactive T cells has also the1176 Journal of Hepatology 2014advantage to cause minimal ‘‘off-target’’ reactivity (cross-reactiv-
ity) and thus avoiding the severe side effects that have been
described in some recent cancer immunotherapy trials [4,5].
Despite the remarkable results, the data have been obtained
from a single patient and the feasibility of such a method has
to be evaluated in more patients with different epithelial cancers
to analyze the extent to which tumour mutations can be targeted
by adoptive T cell therapy. Furthermore, the approach described
in this report is perhaps limited to cancers where there are few
mutations, as screening hundreds of mutations for immunogenic-
ity is technically challenging with the current technology and
there is also the risk that an already genetically unstable tumour
might simply escape the immune attack via downregulation of
the target protein. There has been evidence in human studies
suggesting that effective immunotherapy might lead to cancervol. 61 j 1175–1177
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immunoediting [6,7]. Given the heterogeneity of the majority of
cancers, it is difﬁcult to predict if targeting a single mutation epi-
tope might result in durable tumour control or selection of
immunoresistant tumour variants that might accelerate tumour
progression [8]. Nevertheless, the authors commented that
‘‘mapping of the mutational landscape of human cancer is occur-
ring at rapid pace but clinical strategies to exploit such knowl-
edge for clinical beneﬁt remain to be realized’’; perhaps in the
near future it might be possible to apply multi-epitope-based
cancer immunotherapies in the clinic.
This pioneering work opens the new exciting possibility to
develop real personalized immune based targeted therapy for
many different cancers. Sequences of proteins expressed by
tumours could be used to detect mutations or the presence of
other ‘‘non-self proteins’’ like for example viral antigens, that
should be highly represented in hepatitis B virus (HBV)-related
HCC (where a high frequency of HBV-DNA integration is known
to occur) [9], and target them with T cells expanded from the
tumours or T cells engineered to express speciﬁc T cell receptors
[10].
The experimental framework to translate such knowledge
into new therapies has been provided. The realization of clinical
beneﬁts for cancer patients might not be such a distant reality.Conﬂict of interest
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